The six currently approved U.S. Food and Drug Administration (FDA) EGFR inhibitors have demonstrated excellent efficacy regarding objective response rate and prognosis in EGFR-positive NSCLC, with fewer adverse effects [9,10]. Here, EGFR is linked to non-small cell lung carcinoma.